Actively Recruiting

Age: 18Years +
All Genders
NCT07058454

Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies

Led by Sixth Affiliated Hospital, Sun Yat-sen University · Updated on 2025-12-29

5000

Participants Needed

1

Research Sites

121 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging. The goal is to develop a predictive model for major adverse cardiovascular events (MACE) in this population by integrating both local factors (e.g. central venous catheter-related thrombosis) and systemic factors (e.g. age, comorbidities, genetic predisposition). An active surveillance system employing periodic cardiac evaluations (ECG, echocardiography) and biomarker measurements (troponin T, NT-proBNP) will enable early detection of cardiotoxic effects. The impact of these adverse events and the monitoring strategy on patients' quality of life will also be assessed.

CONDITIONS

Official Title

Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults over 18 years old with a confirmed diagnosis of any type of cancer
  • Currently receiving or planning to receive chemotherapy including molecular targeted drugs as adjuvant treatment
  • Willing and able to provide informed consent and clinical data and biological samples for the study
Not Eligible

You will not qualify if you...

  • Missing key patient information or medical records needed for the study
  • Did not complete the full planned chemotherapy course at the study center
  • History of severe acute cardiovascular or cerebrovascular events within 6 months before enrollment, such as acute heart failure, heart attack, stroke, malignant arrhythmia, or severe heart failure (NYHA Class IV/V)
  • Did not complete essential pre- or post-chemotherapy tests including blood routine, liver/kidney function, coagulation, cardiac enzymes (troponin T), NT-proBNP (or BNP), 12-lead ECG, and echocardiogram

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sixth Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 5106555

Actively Recruiting

Loading map...

Research Team

X

xiaoyan li

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here